Nurix Therapeutics, Inc. (NRIX) — Stock Score Summary

Nurix Therapeutics, Inc. (NRIX) has a MoatMap StockRank of 22/100 based on Quality (26/100), Value (35/100), and Momentum (46/100) factor scores. The current signal is SELL. Nurix Therapeutics is a clinical-stage biotech company. While its targeted protein degradation platform is innovative, it is pre-revenue and does not align with our CDMO pricing power theme, which focuses on validated manufacturing gatekeepers.

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and inflammatory diseases. The company's competitive moat is centered on its proprietary DELigase discovery platform, which enables the design of small molecules that harness the body's natural ubiquitin-proteasome system. It operates as a leading innovator in the high-potential protein degradation space, backed by strategic collaborations with global pharmaceutical leaders.

Key Financial Metrics

Price$15.64
Market Cap$1.8B
P/E (Forward)-5.33
Price/Book3.29
Return on Equity-61.4%
Return on Invested Capital-47.5%
Debt/Equity12.20
Gross Margin0.0%
Operating Margin-1479.4%
Revenue Growth-66.1%
Free Cash Flow$-145M

Nurix Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Nurix Therapeutics, Inc.’s (NRIX) StockRank?
MoatMap’s StockRank for Nurix Therapeutics, Inc. (NRIX) is 22/100, with a Sell signal. It is a composite of Quality (26), Value (35), and Momentum (46) factor ranks across MoatMap’s 19,000+ stock universe.
Does Nurix Therapeutics, Inc. have an economic moat?
Nurix Therapeutics, Inc. (NRIX) has a Quality factor score of 26/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Nurix Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Nurix Therapeutics, Inc. (NRIX) is Sell, based on a StockRank of 22/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Nurix Therapeutics, Inc. in?
Nurix Therapeutics, Inc. (NRIX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksNRIX deep dive reportAI ChampionsHow we score stocksSense-check another stock